CAU
HRMY icon

Caxton Associates (UK)’s Harmony Biosciences HRMY Stock Holding History

Caxton Associates (UK)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,450
Closed -$453K – 847
2025
Q3 		$453K Buy
+16,450
New +$567K 0.01% 477

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caxton Associates (UK)'s HRMY Position: Q4 2025 in Review

Caxton Associates (UK) sold out of Harmony Biosciences (HRMY) in Q4 2025, closing a stake of 16,450 shares — an estimated $453K sold.

Caxton Associates (UK) first reported a position in HRMY in Q3 2025 and held it in 1 quarter. The position peaked at $453K in Q3 2025. 323 funds tracked by Wall St. Rank hold HRMY as of Q4 2025.

  • Caxton Associates (UK) reported no remaining Harmony Biosciences position as of Q4 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 16,450 Harmony Biosciences shares in Q4 2025, an estimated $453K.
  • Caxton Associates (UK) first reported a position in Harmony Biosciences in Q3 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Harmony Biosciences position peaked at $453K in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.